Lake Street analyst Frank Takkinen notes that small cap healthcare remains range bound while larger cap indices continue to make all-time highs and presents investors with five “bargain bin” ideas for the second half that have solid fundamentals, trade below the comp group averages, grow double-digits, and have novel technologies that the firm sees supporting durable growth or a strategic takeout. The firm highlighted Artivion (AORT) with a $30 price target, Lensar (LNSR) with an $8 target, NeuroPace (NPCE) with a $20 target, Pulmonx (LUNG) with a $12 target and TELA Bio (TELA) with a $14 price target, all of which are Buy-rated.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AORT:
Questions or Comments about the article? Write to editor@tipranks.com